Navigation Links
Mayo Clinic: Raoul Tibes, M.D., Ph.D., to receive Career Development Award

CHICAGO -- Rauol Tibes, M.D., Ph.D., the associate director of the Acute and Chronic Leukemias Program at Mayo Clinic in Arizona, will receive a Career Development Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (formerly known as the ASCO Cancer Foundation) at the annual ASCO meeting this weekend in Chicago.

VIDEO ALERT: Additional audio and video resources are available at the Mayo Clinic News Blog.

Dr. Tibes is one of only eight researchers in the United States selected to receive the Conquer Cancer Foundation of ASCO Career Development Award this year. The award, a three year grant totaling $200,000, will help fund the next phase of Mayo Clinic's translational research in acute myeloid leukemia (AML) led by Dr. Tibes and his team of colleagues.

The Career Development Awards are presented to physicians who are within their first to third year of full-time, primary faculty appointment in a clinical department at an academic medical institution.

"I am very happy and proud," said Dr. Tibes, upon learning that his research effort from his laboratory, designed to advance new therapies for patients with acute leukemias, was recognized with this honor.

The crux of this translational research focuses on how to make the drug Cytarabine (one of the most actively used drugs administered to leukemia patients), more potent and effective, particularly for leukemia patients who have failed prior therapies and whose leukemia has relapsed.

Dr. Tibes said this kind of translational research project was greatly accelerated when he and his team began adapting RNA interference (RNAi) to leukemia research.

"We performed a large scale RNAi screening knocking down (or inhibiting) 572 kinases (genes that drive growth)," explained Dr. Tibes. "As a result, when the WEE1 kinase was inhibited, a more potent effect of Cytarabine was produced."

"This technology allowed us to select the gene, out of hundreds to thousands of genes, that most strongly enhances the activity of Cytarabine. This is a tremendous selection to pick the "winner" gene that can then be targeted with new drugs together with Cytarabine," said Dr. Tibes, who, along with his laboratory team, is performing similar RNAi screens for other commonly used cancer drugs with the goal of accelerating the design of new therapies for Mayo Clinic.

Dr. Tibes said the proposed next step is to take the positive findings of the Cytarabine combination with the WEE1 kinase inhibitor he has seen in the laboratory setting and translate it to a clinical trial to see if it is a more effective therapy for patients with advanced, acute and chronic leukemias.

"One of our goals at Mayo Clinic is to improve patient care through translational research," said Keith Stewart, M.B.Ch.B., dean of research at Mayo Clinic in Arizona. "It is our hope this research may offer leukemia patients a treatment alternative when standard therapies fail," Dr. Stewart added.

"One of the big challenges, especially for acute leukemias, is that therapies haven't changed in decades. The treatment of acute leukemias, specifically AML has lagged behind. We aim to find new therapeutic combinations for patients with this research," said Ruben Mesa, M.D., chair, Division of Hematology and Medical Oncology at Mayo Clinic in Arizona.


Contact: Julie Janovsky-Mason
Mayo Clinic

Related medicine news :

1. Atlanta School of Massage Celebrates 30th Anniversary with a New Green Design and New Name for its Teaching Clinic: SensAbility
2. AMA Honors Vice Admiral John Mateczun, M.D., With Top Government Service Award
3. Nationally Known Interventional Neuroradiologist John Pile-Spellman, M.D., Joins Neurological Surgery, P.C.
4. University of Utah afib specialist, Marcos Daccarett, M.D., wins Young Investigator Award
5. Joan Miller, M.D., receives 2010 Leadership Award for the Advancement of Women Faculty
6. Gino Tutera, M.D., F.A.C.O.G. Brings SottoPelle Therapy to Middle Tennessee, Opens Practice in Nashville Medical District
7. Renowned Psychiatrist, Lyubov Y Gorelik, M.D., is selected to represent New York in The Leading Physicians of the World
8. Anthony S. Fauci, M.D., on results from the CAPRISA 004 microbicide study
9. O. Marion Burton, M.D., F.A.A.P., addresses American Academy of Pediatrics in new term as president
10. Douglas A. Jabs, M.D., honored with Jackson Memorial Lecture by the American Academy of Ophthalmology
11. Donald M. Lloyd-Jones, M.D., recipient of the American Heart Associations 2010 Chairmans Award
Post Your Comments:
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: